ArticleJournal of oral and maxillofacial pathology : JOMFP2025
Medication-related osteonecrosis of the jaw in patient with McCune-Albright syndrome: A rare case report.
Article in Journal of oral and maxillofacial pathology : JOMFP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
McCune-Albright Syndrome (MAS) is a rare disorder characterized by the combination of two or more classic features: Fibrous dysplasia of bone, café-au-lait skin macules and hyperfunctioning endocrinopathies. Bisphosphonates are commonly administered in these patients to mitigate bone lesions and relieve pain; despite the benefits of this medication, its use places patients at risk for medication-related osteonecrosis of the jaws (MRONJ) making it essential to obtain a thorough medical history prior to any oral surgical procedure. The aim of this study was to present a rare case of MRONJ in a 29-year-old female patient with MAS, who had been receiving intravenous zoledronate for seven years and was submitted to the upper right impacted third molar removal. MRONJ remains a challenging condition with no standardized treatment protocol. In the present case, bone sequestrum removal combined with Platelet-Rich Fibrin and buccal fat pad grafting, along with pentoxifylline and tocopherol therapy, yielded positive outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.